atepeq/tico19 huggingface dataset:
Other research directions include the development of a COVID-19 vaccine and convalescent plasma transfusion.SARS-CoV-2 has about 66 druggable proteins, each of which has multiple ligand binding sites.
Qiimaynta goobahaas la isku daray waxa ay bixiyaan saadaal macquul ah oo lagu samaynayo borootiin wax ku ool ah oo fayrus disha COVID-19.
Analyzing those binding sites provide the reasonable project of developing effective antiviral drug against COVID-19 proteins.
Waxaa kamid ah botooriinta la bartilmaameedsanayo SARS-CoV-2 ee ugu muhiimsan papain-sida protease, RNA ku tiirsan RNA polymersare, helicase, S borootiin, iyo ADP ribophosphatase.
Of the most important SARS-CoV-2 target proteins are papain-like protease, RNA dependent RNA polymerase, helicase, S protein, and ADP ribophosphatase.
Hussein A A, et al waxa uu daraasadeeyay dhawr curiye taas oo kadibna loo isticmaalay oo laguna qiimeeyay waxay ka samaysan yihiiin si lamid ah dawooyinka sare ee la ansixiyay si loo xawaareeyo waxa ay ka kooban tahay dawada lagula dagaalamayo SARS-CoV-2 ee daraasada tijaabada kahor si loogu soo saaro qaabka daraasada tijaabada.
Hussein A A, et al studied several candidate compounds which then optimized and analyzed for their skeleton similarity with the highest similar approved drugs in order to accelerate a potent anti-SARS-CoV-2 drug development in his preclinical study to be recommended in a clinical study design.
Chloroquine waxaa weeye dawo lagula dagaalamo malariyada taas oo sidoo kale loogu isticmaalay qaar akmid ah xanuunada difaaca si toos ah.
Chloroquine is an anti-malarial medication that is also used against some auto-immune diseases.
Maarso 18, WHO waxay ku dhawaaqday in chloroquine iyo wixii la xidhiidha hydroxychloroquine inay noqon doonaan qaar kamid ah afarta dawo ee qayb ka noqonaya daraasada tijaabada caafimaadka ee Midawga.
On 18 March, the WHO announced that chloroquine and the related hydroxychloroquine would be among the four drugs studied as part of the Solidarity clinical trial.
Badhasaabka New York Andrew Cuomo waxa uu ku dhawaaqay in tijaabooyinka Gobolka New York ee chloroquine iyo hydroxychloroquine ay bilaa doonaan 24 Maarso. 28 Maarso, FDA waxay ogolaaday isticmaalka hydroxychloroquie sulfate iyo chloroquine phosphate oo lagu istimcaalka Ogolaanshaha Isticmaalka Xaalada Degdeg ah (EUA).
New York governor Andrew Cuomo announced that New York State trials of chloroquine and hydroxychloroquine would begin on 24 March.On 28 March, the FDA authorized the use of hydroxychloroquine sulfate and chloroquine phosphate under an Emergency Use Authorization (EUA).
Daawaynta umay ansixin FDA si loogu sameeyo tijaabo caafimaad waxaana lagu ansixiyay oo ay hoos timaadaa EUA kaliya iyada oo ah daawayn tijaabo ah oo xaalada degdeg ah loogu isticmaalayo bukaanka la dhigay isbitaalka laakiin aan loo haynin daawayn tijaabo caafimaad ku jirta.
The treatment has not been approved by the FDA's clinical trials process and is authorized under the EUA only as an experimental treatment for emergency use in patients who are hospitalized but are not able to receive treatment in a clinical trial.
CDC waxa ay sheegtey in "isticmaalka, xadiga, ama mudada hydroxychloroquine ee prophylaxis ama daawaynta SARS-CoV-2 caabuqa ah" aan weli la ogaan.
The CDC has said that "the use, dosing, or duration of hydroxychloroquine for prophylaxis or treatment of SARS-CoV-2 infection" are not yet established.
Dhakhaatiirtu waxay sheegeen inay isticmaalaan dawadan mark ay hirin dawo "ikhtiyaar kale oo jiraayi".
Doctors have said they are using the drug when "there's no other option".
Koox daraasadeed oo Turkish ah ayaa Istanbul ku sameeyay daraasad yar iyada oo ay isticmaalayaan chloroquine lagu daray zinc, fiitaamiin A, fiitaamiin C iyo fiitaamiin D.
A Turkish research team in Istanbul is conducting a small study on the use of chloroquine in combination with zinc, vitamin A, vitamin C and vitamin D.
Daraasado waawayn ayaa ka socda Jaamacada Duke iyo Jaamacada Oxford.
Large studies are underway at Duke University and the University of Oxford.
Dugsiga Caafimaadka NYU Langone waxa uu wadaa tijaabada amaanka iyo wax ku oolnimada isticmaalka kahortaga ee hydroxychloroquine.
NYU Langone Medical School is conducting a trial on the safety and efficacy of preventative use of hydroxychloroquine.
Tijaabooyin caafimaad oo Jayna ku samaysay Wuhan iyo Shenzhen waxaa lagu sheegey in lagu arkay in favipiravir "waxtarkeedu cad yahay"
Chinese clinical trials in Wuhan and Shenzhen claimed to show favipiravir was "clearly effective".
Bukaano 35 ah oo ku sugan Shenzhen waxaa laga waayay qaybta 4 maalmood ah, halka mudada xanuunka uu ahaa 11 maalmood 45 bukaan oo aan la siinin dawada.
35 patients in Shenzhen tested negative in a median of 4 days, while the length of illness was 11 days in the 45 patients who did not receive it.
Daraasad lagu sameeyay 240 bukaan oo qaba xanuunada sanbabka, kala badh ayaa lasiiyay favipiravir oo kala badhna waxaa lasiiyay umifenovir.
In a study conducted in Wuhan on 240 patients with pneumonia, half were given favipiravir and half received umifenovir.
Hay'ada Dawooyinka Talyaaniga ayaa shacabka u sheegtey inay jiraan cadaymo sheegaya in dawada weli la tijaabinayo oo ay weli hordhac tahay.
The Italian Pharmaceutical Agency reminded the public that the existing evidence in support of the drug is scant and preliminary.
Abriil 2, Jermalku waxa uu ku dhawaaqay in uu ka iibsanayo dawo Jabaan kaydkeeda, oo uu u isticmaali doono in ciidanku dawadaas keeno isbitaalada jaamacadaha, halaas oo dawada loo isticmaali doono in lagu daweeyo bukaanada COVID-19.
On 2 April, Germany announced that it would purchase the drug from Japan for its stockpile, and use the military to deliver the drug to university hospitals, where the drug will be used to treat COVID-19 patients.
Si lagu daabacay South Chine Morning Post, Shinzo Abe waxa uu u jawaabay maamulka Trump ee ku saabsan iibsiga dawada. Dawada waxaa dhici karta inayna waxba u tarin xanuunada fayruska uu marka hore tarmay.
According to the South China Morning Post, Shinzo Abe has made overtures to the Trump administration about purchasing the drug.The drug may be less effective in severe cases of illness where the virus has already multiplied.
Waxaa dhici karta inayna amaan ahayn inay isticmaalaan dumarka uurka leh ama kuwa isku dayaya inay qaadaan.
It may not be safe for use by pregnant women or those trying to conceive.
Hal daraasadeed oo lagu sameeyay lopinavir/ritonavir (Kaletra), isku darta dawada fayruska ee lopinavir iyo ritonavir, "ayaan wax faa'ido ah lagu arag".
One study of lopinavir/ritonavir (Kaletra), a combination of the antivirals lopinavir and ritonavir, concluded that "no benefit was observed".
Dawada waxaa loogu talo geley dadka la nool HIV si ayna u badalin isku darka protease.
The drugs were designed to inhibit HIV from replicating by binding to the protease.
Koox cilmi baadhayaal ah oo ka socota Jaamacada Colorado ayaa isku dayaya inay wax ka badalaan dawooyinka si ay u helaan curiyayaal isku daraya protease-ka SARS-CoV-2. Waxaa jira dhaleecayn ay bulshada sayniska oo ku saabsan jihaynta khayraadka si dib loogu isticmaalo wixii sida gaarka ah loogu sameeyay HIV/Aydhis.
A team of researchers at the University of Colorado are trying to modify the drugs to find a compound that will bind with the protease of SARS-CoV-2.There are criticisms within the scientific community about directing resources to repurposing drugs specifically developed for HIV/AIDS.
WHO waxay ku dartay lopinavir/ritonavir tijaabada Midnimada ee caalamiga ah.
The WHO included lopinavir/ritonavir in the international Solidarity trial.
Remdesivir waxa curiyay oo sameeyay Gilead Sciences si loogu daweeyo fayruska Ebola iyo fayruska Marburg. Gilead Sciences waxay markii danbe soo saareen Remdesivir kaas oo lahaa hawlo dawada faryiska ah ee vitro oo dhawr filo-, pneumo-, paramyxo, iyo corona - fayrus ah.
Remdesivir was created and developed by Gilead Sciences as a treatment for Ebola virus disease and Marburg virus infections . Gilead Sciences subsequently discovered that Remdesivir had antiviral activity in vitro against multiple filo-, pneumo-, paramyxo-, and corona- viruses .
Hal mushkilad ayaa ah in daawaynta loo sameeyay in la iskaga caabiyi badalka ay horseedi karto dhawr xanuun iyo safmar.
One issue with antiviral treatment is the development of resistance through mutations that can lead to more severe disease and transmission.
Qaar kamid ah daraasad lagu sameeyay remdesivir ayaa muujinaya inay leedahay caqabad sare oo hide sidaha ah oo iska caabin ah. Waxaa jira dhawr tijaabo caafimaad oo socda, oo ay ku jiraan laba lagu samaynayo Isbitaalada Jaamacada Cleveland; mid kamid ah dadka qaaba xanuunka oo sahlan iyo kuwa qaba xanuunka oo aad u daran.
Some early pretrial studies suggest remdesivir may have a high genetic barrier to resistance.There are several clinical trials underway, including two conducted by Cleveland University Hospitals; one for people with moderate illness and another for those with more severe illness.
Waxaa jira tijaabo caafimaad oo socda oo qaadashada fiitaamiin C ee dadka la dhigay isbitaalka iyo kuwa qaba xanuunada daran ee COVID-19; laba placebo oo la xakameeyay (Jayna, Kanada) iyo hal aan la xakamaynin (Talyaaniga).
There are three ongoing clinical trials of intravenous vitamin C for people who are hospitalized and severely ill with COVID-19; two placebo controlled (China, Canada) and one with no control (Italy).
Gobolka New York ayaa bilaabay tijaabada antibootiga azithromycin 24 Maarso 2020.
New York State began trials for the antibiotic azithromycin on 24 March 2020.
Xarunta Qaran ee Jabaan ee Caafimaadka iyo Dawooyina Caalamka (NCGM) waxa ay qorshaynaysaa tijaabada caafimaad ee Teijin Alvesco (ciclesonide), dawada la nuugo ee corticosteroid ee xiiqda, si loogu daweeyo bukaanka kahor inta ayna yeelan xanuunka novel coronavirus.
Japan's National Center for Global Health and Medicine (NCGM) is planning a clinical trial for Teijin's Alvesco (ciclesonide), an inhaled corticosteroid for asthma, for the treatment of pre-symptomatic patients infected with the novel coronavirus.
Waa qaab angiotensin-loo badalayo enzyme 2, tijaabada Wajiga II ayaa ku socoto 200 oo bukaan oo laga soo qaata dadka uu xanuunka adag hayo, loona dhigay isbitaalka Denmark, Jarmany, iyo Awstariya si loo ogaado saamaynta daawaynta wax ku oolka ah.
A form of angiotensin-converting enzyme 2, a Phase II trial is underway with 200 patients to be recruited from severe, hospitalized cases in Denmark, Germany, and Austria to determine the effectiveness of the treatment.
Cilmi baadhayaal ka socda Montreal Heart Institute ee Kanada ayaa wakhti xaadirkan baadhaya kaalinta colchicine ay ka ciyaari karto yaraynta ololka iyo mushkilada baabacada ee bukaanka leh xanuunka waxoogagaa ah ee COVID-19.
Researchers from the Montreal Heart Institute in Canada are currently studying the role of colchicine in reducing inflammation and pulmonary complications in patients suffering from mild symptoms of COVID-19.
Daraasada, oo loo bixiyay COLCORONA, waxa loosoo qaatay 6000 oo qof oo waawayn oo ah 40 jir iyo wixii ka wayn oo laga heley COVID-19 oo markaa leh xanuun dhexaad ah oo aan u baahan in isbitaal la dhigo.
The study, named COLCORONA, is recruiting 6000 adults aged 40 and over who were diagnosed with COVID-19 and experience mild symptoms not requiring hospitalization.
Dumarka uurka leh ama naaska nuujinaya ama aan qaadan dhalmo baajiye wanaagsan uma qalmaan.
Women who are pregnant or breastfeeding or who do not have an effective contraceptive method are not eligible.
Dhawr anticoagulants ayaa la wadaa tijaabadooda Talyaaniga.
Several anticoagulants are being tested in Italy.
Molokuyuurada miisaanka yar ee heparin ayaa si balaadhan loogu isticmaalaa daawaynta bukaanka, taas oo keentey in Hay'ada Dawooyinka Talyaanigu ay soo saarto tilmaamaha sida loo isticmaalayo.
Low-molecular-weight heparin is being widely used to treat patients, prompting the Italian Medicines Agency to publish guidelines on its use.
Daraasad xarumo badan ah oo 300 oo bukaan ka qayb galayaan ayaa loo isticmaalaya enoxaparin sodium ee prophylaxis iyo dawo lagu daweeyo oo lagaga dhawaaqay Talyaaniga Abriil 14.
A multicenter study on 300 patients researching the use of enoxaparin sodium at prophylaxis and therapeutic dosages was announced in Italy on April 14.
Maadaama oo SARS-CoV-2 uu yahay fayrus, saynisyo badan ayaa diirada saaraya dib u isticmaalka dawada hore loo ansixiyay ee fayruska taas oo la sameeyay wixii ka horeeyay inta aanu safmarku soo bixin MERS, SARS iyo fayruska Galbeedka Nile.
Since SARS-CoV-2 is a virus, considerable scientific attention has been focused on repurposing approved anti-viral drugs that were developed for prior outbreaks such as MERS, SARS, and West Nile virus.
Ribavirin: ribavirin ayaa lagu taliyay in lagu daweeyo COVID-19 si ku cad tilmaamaha nuqulka 7aad ee Jayna.
Ribavirin: ribavirin was recommended for COVID-19 treatment according to Chinese 7th edition guidelines
Umifenovir: umifenovir ayaa lagu taliyay in lagu daweeyo COVID-19 si ku cad tilmaamaha nuqulka 7aad ee Jayna.
Umifenovir: umifenovir was recommended for COVID-19 treatment according to Chinese 7th edition guidelines
Antibootiga qaar ayaa la ogaaday in ay dhicin karto in dib loogu isticmaalo daawaynta COVID-19.
Some antibiotics that have been identified as potentially repurposable as COVID-19 treatments:
Tocilizumab (Anti-IL-6 qaataha): Ayay Jayna Ansixisay.
Tocilizumab (Anti-IL-6 receptor): Approved by China.
Sidoo kale tijaabada Talyaaniga iyo Jayna. Eeh Tociluzuman#COVID-19.
Also trials in Italy and China. and see Tocilizumab#COVID-19.
Weli ma cada xaalada ka iman karta inta uurka la leeyahay oo ay ku jiraan macaanka, wadne xanuunka, hypercoagulability ama kacsanaan taas oo khatar dheeraad ah ku keeneysa dadka uurka leh maadaama oo loogu talo geley dadka aan uurka lahayn. Macluumaadka kooban ee laga hayo, u wareego qaybta sadexaad ee uurka ayaa dhici karta inayna iman, ama inay siday ku timaadaa ay yaraato.
It is unclear yet whether conditions arising during pregnancy including diabetes, cardiac failure, hypercoagulability or hypertension might represent additional risk factors for pregnant people as they do for nonpregnant people.From the limited data available, vertical transmission during the third trimester probably does not occur, or only occurs very rarely.
Ma jirto weli macluumaadka laga hayo uurka intiisa hore.
There is no data yet on early pregnancy.
Cadaymo yar ayaa jirta oo lagu ogolaanayo wixii gunaanad wax ku ool ah ee nooca xanuunka COVID-19 ee dumarka uurka leh.
Little evidence exists to permit any solid conclusions about the nature of COVID-19 infection in pregnancy.
Kiisaska aadka u daran 43 dumar ah oo ka yimid New York oo laga heley COVID-19 ayaa lagu arkay qaab lamid ah dumarka waawayn ee aan uurka lahayn: 86% waxau yeeshaan xanuun yar, 9.3% waxay yeesheen xanuun adag, oo 4.7% waxay yeesheen xanuun aad iyo aad u daran.
A case series of 43 women from New York who tested positive for COVID-19 showed similar patterns to non-pregnant adults: 86% had mild disease, 9.3% had severe disease and 4.7% developed critical disease.
Dhimasho ayaa looga baqday laba.
Fetal distress was reported in two.
Waxba kamid ah dumarka may yeelan xanuunka sanbabka oo daran oo COVID-19 ah ama dhiman.
None of the women developed severe COVID-19 pneumonia or died.
Dhamaantood waxay dhaleen ilmo nool oo wax aad u daran oo neonatal asphyxia ah lagula arag.
All of them had live birth pregnancies and no severe neonatal asphyxia was observed.
Muunad laga qaaday caanaha naaska, dheecaanka amniotic, dhiiga sudunta iyo cunaha candhuuf aha ayaa laga baadhay SARS-CoV-2, oo dhamaantoodna waa laga waayay. Daraasad kale oo lagu sameeyay 15 dumar ah oo uur leh, badanaa bukaanka waxaa ay lahaayeen xumad iyo qufac, halka shaybaadhkooda loo isticmaalay lymphoctopenia 12 bukaan.
The samples of breast milk, amniotic fluid, cord blood and neonatal throat swab were tested for SARS-CoV-2, and all results were negative.In another study on 15 pregnant women, majority of the patients presented with fever and cough, while laboratory tests yielded lymphocytopenia in 12 patients.
Waxa lagu sameeyay shaybaadh tomography bukaankan kuwaas oo waxa ay lamid noqdeen bukaankii hore ee aan uurka laahyn, oo waxa ay ka koobnaayeen wakhtiyada hore opecities.
Computed tomography findings of these patients were consistent with previous reports of non-pregnant patients, consisting of ground-glass opacities at early stage.
Sawir la socod ah kadib dhalmada waxa ay muujiyeen inaanu ku kordhin xanuunada sanbabku. Warbixin saxaafada ah ayaa sheegtey in wax ka badan 100 dumar ah oo qaba COVID-19 ay dhici karto inay dhaleen, oo Maarso 2020, lama sheegin wax dhimasho hooyo ah.
Follow-up images after delivery showed no progression of pneumonia.Media reports indicate that over 100 women with COVID-19 might have delivered, and in March 2020, no maternal deaths were reported.
Tilmaamahani markaa waxay sheegayaan in dadka uurka leh ee la dhigo isbitaalka ee qaba COVID-19 ay tahay inay qaataan ugu yaraan 10 maalmood prophylactic miisaanka molokulaaradiisu yar yihiin oo heparin kadib marka ay ka baxaan isbitaalka.
Their guidelines thus advise that any pregnant person admitted to hospital with a COVID-19 infection should receive at least 10 days of prophylactic low-molecular-weight heparin after being discharged from the hospital.
Mar jirto weli wax macluumaad ah oo sheegeysa in COVID-19 oo keeno mushkilad foosha ah.
There are no data yet concerning the implications of COVID-19 infections for labour.
Ilmo yar oo gabadh ayay dhahsay hooyada qabta COVID-19 taas oo heerkeeda IgM uu aad u sareeyay laba saacadood kadib dhalmada, taas oo muujinaysa in ay ka qaaday utero oo xoojinaysa inay jirto u gudbin mararka qaar.
One infant girl born to a mother with COVID-19 had elevated IgM levels two hours after birth, suggesting that she had been infected in utero and supporting the possibility of vertical transmission in some cases.
Daraasad yar oo lagu sameeyay 6 dumar ah oo laga heley COVID-19 ayaa lagu sheegey inayna jirin wax SARS-COV-19 oo laga heley cunaha ilmaha markaa dhashay, ama serum laakiin antiboodhi ayaa laga heley dhiiga ilmaha muunada sera, oo ay ku jiraan IgM laba ilme.
A small study involving 6 confirmed COVID-19 mothers showed no indication of SARS-COV-19 in their newborns' throats or serum but antibodies were present in neonatal blood sera samples, including IgM in two of the infants.
Maaha wax lala yaabo in hooyadu ay u gudbiso ilmaha markaa daraasd dheeraad ah ayaa lagu samaynaya si loo ogaado hadii fayruska mandheerta uu ka gudbay iyo hadii madheerta gacasha ee daraasada lagu samaynayaa ay waxyeelawday ama ayna caadi ahayn.
This is not usually passed from mother to fetus so further research is required to know whether the virus crossed the placenta or whether placentas of women in the study were damaged or abnormal.
Maadaama oo COVID-19 uu leeyahay waxyaabo badan oo uu uga eeg yahay SARS-CoV iyo MERS-CoV, waxay u badan tahay in saamayntooda dumarka uurka lehi ay isku mid noqonayso.
Since COVID-19 shows similarities to SARS-CoV and MERS-CoV, it is likely that their effect on pregnancy are similar.
Afarka kamid ah todoba dumar ah oo ku jiray qaybtii hore ee uurka ayuu kasoo dhacay ilmihii, laba kamid ah shan dumar ah ayuu xadidmay korniinka ilmahooda qaybta labaad ee uurka, iyo afar kamid ah shan dumar ah ayaa wakhti hore dhalay ilmihii.
Four of seven had first trimester miscarriage, two of five had fetal growth restriction in the second trimester, and four of five had preterm birth.
Waxba caruurtaas may qabin SARS-CoV.
None of the newborns were infected with SARS-CoV.
Warbixinta toban ruux oo uu ku dhacay MERS-CoV dumar uur leh Sucuudiga ayaa muujiyay jiritaanka caafimaad inuu kala duwan yahay, oo uu markaa yahay caabuq dhexe ilaa mid daran.
A report of ten cases of MERS- CoV infection in pregnancy in Saudi Arabia showed that the clinical presentation is variable, from mild to severe infection.
Natiijada kasoo baxday waxay ahayn midii la doonayay badanaa, laakiin dhimashada ilmaha ayaa ahayd 27%. Qiimaynta dhawaan lagu sameeyay COVID-19 ayaad moodaa inuu khatartiisu kaga yar tahay hooyada iyo hooyada marka loo eego SARS iyo MERS laakiin waxaa kordhaysa khatarta in ilmuhu isaga oo aan gaadhin wakhtigiisa inuu dhasho wixii ka danbeeya todobaadka 28.
The outcome was favorable in a majority of the cases, but the infant death rate was 27%.A recent review suggested that COVID-19 appeared to be less lethal to mothers and infants than SARS and MERS but that there may be an increased risk of preterm birth after 28 weeks' gestation.
Hay'ada Caafimaadka Adduunka iyo Xarunta Kahortaga iyo Xakamaynta Xanuunada ee Maraykanka aaya kula talinaya dumarka uurka leh inay sameeyaan wax ay samaynayaan shacabku guud ahaan si ay iskaga ilaaliyaan caabuqa, inay afka iyo sanka xidhaan, inay iska ilaaliyaan la macaamilka dadka xanuunsanaya, inay ku farxashaan sabuun iyo biyo ama gacmo nadiifiye.
The World Health Organization and Centers for Disease Control and Prevention of the United States advises pregnant women to do the same things as the general public to avoid infection, such as covering cough, avoid interacting with sick people, cleaning hands with soap and water or sanitizer.
Daraasad lagu sameeyay Shanghai dumarka uurka leh oo ku jira qaybo kala duwan oo mudada uurka ah ayaa lagu sheegey inay baahi wayn u qabaan inay helaan macluumaadka caafimaadka oo online ah iyo adeegyo.
A survey conducted in Shanghai among pregnant women in different trimesters of pregnancy identified a strong demand for online access to health information and services.
Dadka sugaya ilmahoodii kowaad ayaa diyaar u ahaa inay wada tashi iyo tilmaamo online ah helaan marka loo eego dadka hore usoo dhalay. RCOG iyo RCM waxay ku taliyeen in balamo la qabsado 7 maalmood kadib marka la yeesho calaamada xanuunka COVID-19 ama 14 maalmood hadii qof qoyska ahi uu leeyahay calaamado xanuun.
People expecting their first baby were more willing to have online consultation and guidance than who had previously given birth.The RCOG and RCM recommend that in-person appointments be deferred by 7 days after the start of symptoms of COVID-19 or 14 days if another person in the household has symptoms.
Waxyaabo yar ayaa kusoo baxay sadex bukaan oo aan calaamado lahayn.
Fever subsequently developed in three asymptomatic patients.
Hal bukaan oo laga waayay ayaa markii danbe yeeshan astaamo markii danbe ah kaas oo markii danbe laga heley sadex maalmood kadib markii shaybaadhkii kowaad lagaga waayay.
One patient who had tested negative subsequently became symptomatic postpartum and tested positive three days after the initial negative test.
Dhakhtarada sameeyay shaybaadhku waxa ay ku taliyeen si loo yareeyo caabuqa oo loo helo PPE, maadaama oo tirobadan oo bukaan ahi ayna lahayn wax calaamado ah, shaybaadh guud oo dumarka uur leh in lagu sameeyo.
The doctors conducting the screening recommended that in order to reduce infection and allocate PPE, due to high numbers of patients presenting as asymptomatic, universal screening of pregnant patients should be conducted.
Waxay sidoo kale ku taliyeen in dadka looga shakiyo ama lagu xaqiijiyo inay qabaan COVID-19 inay sii wadaan la socodka elektoroonig ahaan ee ilmaha.
They also suggest that people with suspected or confirmed COVID-19 should have continuous electronic fetal monitoring.
Isticmaalka barkada dhalma laguma talinayo wixii dad ah ee looga shakiyo ama la xaqiijiyo inay qabaan COVID-19 maadaama oo khatar badan oo xanuun ahi ay ka iman karto.
The use of birthing pools is not recommended for suspected or confirmed cases of COVID-19 due to the risk of infection via faeces.
Ingiriiska, saraakiishu waxay ku taliyaan in taxadir ahaan in hooyada iyo ilmaha la kala kaxeeyo ee caafimaad qabka ku dhasha taas oo ay tahay in aan la dhayalsan oo ay tahay in meel lagu wada hayo mudada dhalmada kadib inta daryeelka ilmaha aan loo baahnayn. Macluumaadka Jayna laga heleyo ayaa sheegaya in laga kaxeeyo hooyada qabka ilmaha 14 maalmood.
In the UK, official recommendations state that precautionary separation of a mother and a healthy baby should not be undertaken lightly and that they should be kept together in the postpartum period where neonatal care is not required.Literature from China recommended separation of infected mothers from babies for 14 days.
Maraykanka waxaa sidoo kale jira talooyin lamid ah oo ilmaha cusub iyo hooyada ay tahay in si kumeel gaadh ah loo kala kaxeeyo ilaa inta uu ay meesha ka baxayso taxadirka isku gudbinta, iyo marka ayna macquulka ahayn ilmaha cusub in 2 mitir loo jirsiiyo hooyada.
In the US there is also the recommendation that newborns and mothers should be temporarily separated until transmission-based precautions are discontinued, and that where this is not possible the newborn should be kept 2 metres away from the mother.
b' Basaasida COVID-19 waxaa ka mid aha la socodka faafitaanka xanuunka coronavirus si markaa loo ogaado qaabka uu ku faafayo.
b'COVID-19 surveillance involves monitoring the spread of the coronavirus disease in order to establish the patterns of disease progression.
Hay'ada Caafimaadka Adduunka (WHO) waxay ku talinaysaa la socodka firfircoon, taas oo diirada lagu saarayo natiijada, shaybaadhka iyo daba galka meesha laga qaaday ee dhamaan xaalada isu gudbinta.
The World Health Organization (WHO) recommends active surveillance, with focus of case finding, testing and contact tracing in all transmission scenarios.
La socodka aadka u balaadhan ee COVID-19 ayaa la filanayaa in lagula socdo qaabka faafitaanka, in lagula socdo kiisaska cusub, iyo iyada oo laga duulayo macluumaadkan, in la helo macluumaadka faafitaanka oo markaa lagu sameeyo qiimaynta khatarta iyo tilmaamaha u diyaar garawga xanuunka.
COVID-19 surveillance is expected to monitor epidemiological trends, rapidly detect new cases, and based on this information, provide epidemiological information to conduct risk assessment and guide disease preparedness.
Kormeerka astaamaha ayaa ku salaysan calaamadaha shakhsiga ee markaa u dhigma kuwa COVID-19.
Syndromic surveillance is done based on the symptoms of an individual that corresponds to COVID-19.
Maarso 2020, WHO waxay ku talisay in kiisaska soo socda la bayaamiyo:
As of March 2020, the WHO recommends the following case definitions:
Macquul ah inuu qabo: "Cidii laga shakiyo ee laga baadhay fayruka COVID-19 ee natiijadeedu ayna dhamaystirnayn "AMA" cidii laga shakiyo ee shaybaadhka aan lagu samaynin waxay doonto ha noqotee sababtu".
Probable case : "A suspect case for whom testing for the COVID-19 virus is inconclusive" OR "a suspect case for whom testing could not be performed for any reason".
Cida la xaqiijiyo inay qabto: "Qofka uu shaybaadh xaqiijiyay inuu qabo COVID-19, iyada oo aan la eegeynin calaamadaha iyo ishaarada xanuun ee uu leeyahay".
Confirmed case: "A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms".
Isku soo dhawaanshaha tooska ah ee cida ay dhigi karto ama la xaqiijiyo inay qabto;
Direct physical contact with a probable or confirmed case;
Inta loo adeegayo bukaanka ay dhici karto ama la xaqiijiyo inuu qabo COVID-19 iyada oo aan la isticmaalin agabka badbaadada ee munaasabka ah.
Direct care for a patient with probable or confirmed COVID-19 disease without using proper personal protective equipment;
Xaaladaha kale ayaa muujinaya in qiimaynta khatarta ee deegaanka". WHO waxay ku talinaynaa in la sheego wixii looga shakiyo iyo kuwa la xaqiijiyo inay qabaan COVID-19 48 saacadood gudahood marka la ogaado.
Other situations as indicated by local risk assessments".WHO recommends reporting of probable and confirmed cases of COVID-19 infection within 48 hours of identification.
Dalalku waa in ay kiis-kiis u sheegaan ilaa inta macquulka ah, laakiin hadii ay jirto yaraan khayraadka ahi, waxaa loo baahan yahay warbixin todobaadkii oo la isku daro hadii ay macquul tahay.
The countries should report on a case-by-case basis as far as possible, but in case of limitation in resources, aggregate weekly reporting is also possible.
Hay'adaha qaar ayaa sameeyay app-ka dhaqaale lagu uruurinayo oo lagula soconayo calaamadaha, halkaas oo dadku ay soo sheegi karaan calaamadaha ay leeyihiin si ay cilmi baadhayaasha uga caawiyaan khariirad samaynta aagaga uu ku badan yahay calaamadaha COVID-19.
Some organizations have created crowdsourced apps for syndromic surveillance, where people can report their symptoms to help researchers map areas with concentration of COVID-19 symptoms.
Kormeerka fayryska ayaa lagu sameeyay iyada oo la isticmaalkayo shaybaadhka molokulaarada ee COVID-19.
Virological surveillance is done by using molecular tests for COVID-19.
WHO waxay baahisay macluumaad ku saabsan shaybaadhada sida loo sameynayo shaybaadhak COVID-19.
WHO has published resources for laboratories on how to perform testing for COVID-19.
Midawga Yurub, shaybaadhadu waxay xaqiijiyeen in kiisaska COVID-19 lagu sheego 24 saacadood marka la ogaado.
In the European Union, laboratory confirmed cases of COVID-19 are reported within 24 hours of identification.
Ugu yaraan 24 dal ayaa sameeyay la socod dhitaal ah oo dadkooda ah.
At least 24 countries have established digital surveillance of their citizens.
La socodka dhitaalka ah waxaa kamid ah app-baba, macluumaadka goobta iyo sumadayn elektoroonig ahaan.
The digital surveillance technologies include apps, location data and electronic tags.
Xarunta Xakamaynta iyo Kahortaga Xanuunada Maraykanka ayaa la socota macluumaadka socdaalka ee shakhsiyaadka iyada oo isticmaalaysa macluumaadka rakaabka diyaaradaha.
The Center For Disease Control and Prevention in USA tracks the travel information of individuals using airline passenger data.
Hong Kong, maamulka waxa ay ku waajibeen gacan xidhad iyo app inay samaystaan dhamaan dadka socdaalayaayi.
In Hong Kong, authorities are requiring a bracelet and an app for all travellers.
App GPS ah ayaa loo isticmaalaa si loola socdo shakhsiyaadka Koonfurta Kuuriya si loo xaqiijiyo in aan karantiimada la jabin, kas oo digniin u dira isticmaalayaasha iyo maamulka hadii ay ka tabaan aagii loogu talo geley.
A GPS app is used to track the locations of individuals in South Korea to ensure against quarantine breach, sending alerts to the user and to authorities if people leave designated areas.
Singaaboor, shakhsiyaadku waa inay sheegaan meesha ay ku sugayn yihiin iyaga oo isticmaalaya cadayn sawir leh.
In Singapore, individuals have to report their locations with photographic proof.
Taylan waxay isticmaashaa app iyo kaadhka SIM-ka si ay dadka socdaalayaa ay u dhaqan geliyaan karantiimada.
Thailand is using an app and SIM cards for all travelers to enforce their quarantine.
Hay'ada xuquuqda bilaa aadanka ayaa dhaleeceeyay talaabooyinkan, kuwaas oo ka dalbaday dawladaha inayna u isticmaalin safmarka inay keenaan qaab balaadhan oo lagula socoto dadka dhitaal ahaan.
Human rights organizations have criticized some of these measures, asking the governments not to use the pandemic as a cover to introduce invasive digital surveillance.
b' Talaalka COVID-19 waxa weeye mala awaal talaal coronavirus xanuunka 2019 (COVID-19).
b'A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19).
In kasta oo aanu jirin talaal dhamaystay tijaabada, waxaa jirta dhawr iskuday oo socda oo lagu doonayo in lagu sameeyo talaal.
Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.
Dhamaadkii Febraayo 2020, Hay'ada Caafimaadka Adduunka (WHO) waxay sheegey inayna filanaynin in la helo talaal SARS-CoV-2, fayrus daran, in la helo 18 bilood ee soo socda.
In late February 2020, the World Health Organization (WHO) said it did not expect a vaccine against SARS-CoV-2, the causative virus, to become available in less than 18 months.
Shan talaal ayaa lasoo xushay Waji I ee daraasada amaanka ee Abriil.
Five vaccine candidates were in Phase I safety studies in April.
COVID-19 waxaa la ogaaday Diseember 2019.
COVID-19 was identified in December 2019.
Safmar balaadhan oo wada gaashay caalamka 2020, kaas oo horseeday in maalgalin iyo dawlo badan oo daraasadeed lagu sameeyo sidii loo heli lahaa talaal.
A major outbreak spread around the world in 2020, leading to considerable investment and research activity to develop a vaccine.
Hay'ado badan ayaa isticmaalaya cayayaan si looga sameeyo talaalada SARS-CoV-2.
Many organizations are using published genomes to develop possible vaccines against SARS-CoV-2.
Sida la sheegey Abriil, barnaamika CEPI ayaa wada samaynta talaalka oo markaa ku socda xawaare, awooda soo saarka, samaynta miisaanka, iyo helitaanka caalamka.
Stated in April, imperatives of the CEPI initiative for vaccine development are speed, manufacturing capacity, deployment at scale, and global access.
Abriil, Saynisyahabo CEPI ayaa sheegey in 10 madalood oo teknooloojiyad ay socdaan oo daraasadeed oo lagu samanayo inta lagu jiro horaanka 2020 talaal wax ku ool ah oo COVID-19 ah.
In April, CEPI scientists reported that 10 different technology platforms were under research and development during early 2020 to create an effective vaccine against COVID-19.
Madalaha waawayn ayaa bartilmaameedsanaya samaynta amaanka Waji I ee daraasada oo ay ku jiraan:
Major platform targets advanced into Phase I safety studies include:
nucleic aysiidh (DNA iyo RNA) (Waji I waxaa la samaynayaa oo lasoo saarayaa talaalka lasoo xulanayo: Moderna, mRNA-1273)
nucleic acid (DNA and RNA) (Phase I developer and vaccine candidate: Moderna, mRNA-1273)
qaabka fayruska (Wajiga I smaaynta iyo lasoo baxaya talaalka: CanSino Biologics, adenovirus nooca 5 fektor)
viral vector (Phase I developer and vaccine candidate: CanSino Biologics, adenovirus type 5 vector)
Sida ay sheegeen saynisyahanada CEPI Abriil, 115 isku gayn talaal oo lagala soo baxay samaynta hore ee talaalka, oo waxaa la xaqiijiyay 78 mashruuc oo socda (79, sida ay sheegeen Milken Institute), 37 kuwa kale sheegeen, laakiin macluumaad yar ayaa laga hayaa (taas oo la sheegey in la qorsheeyay ama la nashqadeeyay).
As reported by CEPI scientists in April, 115 total vaccine candidates are in early stages of development, with 78 confirmed as active projects (79, according to the Milken Institute), and 37 others announced, but with little public information available (presumed to be in planning or being designed).
Wajiga I-II ee tijaabada ee la qorsheeyay ee amaanka iyo immunogenicity shaybaadhka ah, caadiyan si nasiib ah loola soo baxay, xakamaynta placebo, oo goobo badan ah, inta la ogaanayo wax cad, oo xadi wax ku ool ah.
A Phase I-II trial conducts preliminary safety and immunogenicity testing, is typically randomized, placebo-controlled, and at multiple sites, while determining more precise, effective doses.
Tijaabada Wajiga III caadiyan waxa aku jira ka qayb gal badan, oo ay ku jiraan kooxda la xakamayeeya, iyo wax ku oolnimo tijaabada ee dalaalka kahortaga xanuunka, iyada oo lala socdo saamaynta xun ee ka faa'idaysiga xadida.
Phase III trials typically involve more participants, including a control group, and test effectiveness of the vaccine to prevent the disease, while monitoring for adverse effects at the optimal dose.
79ka talaal ee socda (ee la xaqiijiyay horaankii Abrii 2020), 74 ayaa weli aan lagu qiimayn bilaa aadanka (weli "tijaabada kahor" ayay daraasadu maraysaa).
Of 79 vaccine candidates in active development (confirmed as of early April 2020), 74 were not yet in human evaluation (still in "preclinical" research).
Ilaa 24 Janaayo 2020, Awstaraaliya, Jaamacada Queensland waxay ku dhawaaqday baadhitnaka talaalka molokulaarada ee macquulka ah kaas oo wax ka badali doona hide sidaha borootiinta fayruska si markaa loo sameeyo ficil difaac.
Around 24 January 2020 in Australia, the University of Queensland announced that it is investigating the potential of a molecular clamp vaccine that would genetically modify viral proteins in order to stimulate an immune reaction.
Ilaa 24 Janaayo 2020 Kanada, Xarunta Talaalka Caalamiga ah (VIDO-InterVac) ee Jaamacada Saskatcheman ayaa ku dhawaaqday bilawga shaqada talaalka, taas oo lagu doonayo in lagu bilaabi tijaabada bilaa aadanka 2021.
Around 24 January 2020 in Canada, the International Vaccine Centre (VIDO-InterVac) at the University of Saskatchewan announced the commencement of work on a vaccine, aiming to start human testing in 2021.
Mashaariicda soo saaraya talaalka ayay ku dhawaaqday Xarunta Xakamaynta iyo Kahortaga Xanuunada Jayna 26 Janaayo 2020, Jaamacada Hong Kong 28 Janaayo.
Vaccine development projects were announced at the Chinese Center for Disease Control and Prevention on 26 January 2020, and the University of Hong Kong on 28 January.
Ilaa 29 Janaayo 2020, Shirkada Dawooyinka Janssen, oo uu ay hogaaminayso Hanneke Schuitemaker, ayaa ku dahwaaqay inay bilaabeen samaynta talaal.
Around 29 January 2020, Janssen Pharmaceutical Companies, led by Hanneke Schuitemaker, announced that it had begun work on developing a vaccine.
Janssen waxay soo wada saarayaan talaal afka laga qaado biotechnology, Vaxart.
Janssen is co-developing an oral vaccine with its biotechnology partner, Vaxart.
Maarso 18, 2020, Emergent BioSolutions ayaa ku dhawaaqay inay soo wada saarayaan Vaxart talaalka.
On 18 March 2020, Emergent BioSolutions announced a manufacturing partnership with Vaxart to develop the vaccine.
Febraayo 8 2020, shaybaadhka OncoGen ee Roomaaniya ayaa baahiyay warbixin in uu nashqadeeyay talaal lamid ah ka loo isticmaalo kaansarka neoantigen talaalka ah ee daawaynta.
On 8 February 2020, the laboratory OncoGen in Romania published a paper on the design of a vaccine with similar technology to the one used for cancer neoantigen vaccination therapy.
Maarso 25 madaxa cilmi baadhista ee hay'ada ayaa ku dhawaaqay in ay soo gunaanadeen samaynta talaalka oo ay markaa bilaabayaan tijaabada.
On 25 March the head of the research institute announced that they had finalized the synthesis of the vaccine and were beginning the tests.
Febraayo 27 2020, shirkada ay kaabto Generex, NuGenerex Ummo-Ancology, ayaa ku dhawaaqay in ay bilaabayaan mashruuc talala oo laga sameeyay li-Key peptide talaal ah oo COVID-19 ah.
On 27 February 2020, a Generex subsidiary company, NuGenerex Immuno-Oncology, announced they were beginning a vaccine project to create an Ii-Key peptide vaccine against COVID-19.
Waxay doonayaan inay soo saaraan talaalka lasoo xusho ee markaa lagu tijaabin karo bilaa aadanka "90 maalmood gudahood."
They wanted to produce a vaccine candidate that could be tested in humans "within 90 days."
Maarso 5 2020, Jaamacada Washington ee St. Louis ayaa ku dhawaaqday mashruuca samaynta talaalka.
On 5 March 2020, Washington University in St. Louis announced its projects to develop a vaccine.
Maarso 5 2020, Waaxda Cilmi Baadhista Ciidanka Maraykanka iyo Waaxda Talista ee Fort Detrick iyo Hay'ada Ciidamada Walter Reed Cilmi Baadhista Silver Springs, oo labaduba ku yaala galbeedka Maryland, ayaa ku dhawaaqay inay ka shaqaynayaan talaal.
On 5 March 2020, the United States Army Medical Research and Materiel Command at Fort Detrick and the Walter Reed Army Institute of Research in Silver Spring, both in western Maryland, announced they were working on a vaccine.
Ilaa 10 Maarso 2020, Emergent Biosolution waxay ku dhawaaqeen inay la shaqaynayso Novavax Inc.
Around 10 March 2020, Emergent Biosolutions announced that it had teamed with Novavax Inc.
soo saaritaanka iyo samaynta talaalka.
in the development and manufacture of a vaccine.
Sidoo kale waxay dadku ku dhawaaqeen inay qorshaynayaan tijaabada caafimaadka kahor iyo Wajiga I ee tijaabada caafimaadka Juulay 2020 ugu danbayn.
The partners further announced plans for preclinical testing and a Phase I clinical trial by July 2020.
Maarso 12 2020, Wasiirka Caafimaadka Hindiya ayaa ku dhawaaqay inay la shaqaynayaan 11 qof oo aysoleeshin ku jira, oo ay dedejinayaan si ay ugu yaraan u qaadato wareeg hal sano iyo badh ah ilaa labad sano in la sameeyaa talaalku.
On 12 March 2020, India's Health Ministry announced they are working with 11 isolates, and that even on a fast track it would take at least around one-and-a-half to two years to develop a vaccine.
Maarso 12 2020, Medicago, shirkad bayooteknoolooji ah oo ku taal Magaalada Quebec, Quebec, ayaa sheegtey inay wado samaynta waxyaabo lamid ah coronavirus oo ay qayb kamid ah lacagtiisa bixinayso Hay'ada Kanada ee Daraasada Caafimaadku.
On 12 March 2020, Medicago, a biotechnology company in Quebec City, Quebec, reported development of a coronavirus-like particle under partial funding from the Canadian Institutes for Health Research.
Talaalka laga soo xusho ee shaybaadhka, tijaabada bilaa aadanka ee qorshaynsan Juulay ama Agoosto 2020.
The vaccine candidate is in laboratory research, with human testing planned for July or August 2020.
Horaantii todobaadkaan, The Guardian ayaa daabacay in Madaxweynaha Maraykanka Donald Trump uu siiyay CureVac "lacag badan si ay kaligood u qiimeeyaan talaalka Covid-19", in kasta oo ay dawlada Jermalku ay kasoo horjeedsatay.
Earlier that week, The Guardian reported that the US President Donald Trump had offered CureVac "'large sums of money' for exclusive access to a Covid-19 vaccine", against which the German government protested.
Maarso 17 2020, Shirkada dawooyinka Maraykanka ee Pfizer ayaa ku dhawaaqday inay la shaqaynayso shirkada Jermalka ee BioNTech si ay uga wada shaqeeyaan mRNA-talaalka ah.
On 17 March 2020, American pharmaceutical company Pfizer announced a partnership with German company BioNTech to jointly develop a mRNA-based vaccine.
Talaalka ah mRNA waxa loosoo xushay BNT162, kaas oo wakhti xaadirkan lagu tijaabinayo inta aan caafimaad ahaan la tijaabin oo lana filanayo in la bilaabo tijaabada caafimaadka Abriil 2020.
mRNA-based vaccine candidate BNT162, currently in pre-clinical testing with clinical trials expected to begin in April 2020.
Talyaaniga Maarso 17 2020, Takis Biotech, shirkad Talyaani ah oo baayootek ah ayaa bayaamisay inay heli doonaan natiijada tijaabada caafimaad kahor Abriil 2020, oo talaalka ay doortaan la bilaabi doono in lagu tijaabiyo bilaa aadanka dayrta.
In Italy on 17 March 2020, Takis Biotech, an Italian biotech company announced they will have pre-clinical testing results in April 2020 and their final vaccine candidate could begin human testing by fall.
Faransiiska 19 Maarso 2020, Iskaashiga Barnaamijka U Diyaar Garawga Safmarka (CEPI) waxay ku dhawaaqeen in US$4.9 milyan oo maal galin ah oo COVID-19 ah oo daraasada talaalka iskaashiga ee Istitut Pasteur, Themis Bioscience (Fuyeena, Astariya), Jaamacada Pittsburgh, taas oo ka dhigaysa wadarta CEPI ee maalgelinta talaalka COVID-19 lagu samanayo oo ah US$29 milyan.
In France on 19 March 2020, the Coalition for Epidemic Preparedness Innovations (CEPI) announced a US$4.9 million investment in a COVID-19 vaccine research consortium involving the Institut Pasteur, Themis Bioscience (Vienna, Austria), and the University of Pittsburgh, bringing CEPI's total investment in COVID-19 vaccine development to US$29 million.
CEPI cida kale ee ay ka kaashanayaan ee ka maalgelinaysa samaynta talaalka COVID-19 waa Moderna, Curevac, Inovio, Novavax, Jaamacada Hong Kong, Jaamacada Oxford, iyo Jaamacada Queensland.
CEPI's other investment partners for COVID-19 vaccine development are Moderna, Curevac, Inovio, Novavax, the University of Hong Kong, the University of Oxford, and the University of Queensland.
Maarso 20 2020, saraakiisha caafimaadka ee Ruushka ayaa ku dhawaaqay in saynisyahanadu ay bilaabeen ku tijaabinta xayawaanka til talaal oo lasoo xushay oo kala duwan.
On 20 March 2020, Russian health officials announced that scientists have begun animal testing of six different vaccine candidates.
Cilmi baadhayaasha Imperial College London waxay ku dhawaaqeen in 20 Maarso 2020 ay samayn doonaan talaal RNA oo COVID-19 ah oo iskii ah.
Imperial College London researchers announced on 20 March 2020 that they are developing a self-amplifying RNA vaccine for COVID-19.
Talaalka waxa ay xusheen 14 maalmood gudahood markii ay ogaadeen safmarkii Jayna.
The vaccine candidate was developed within 14 days of receiving the sequence from China.
Dhamaadkii Maarso, dawlada Kanada ayaa ku dhawaaqday inay C$275 milyan ay ku maal gelinayso 96 mashruuc oo daraasadood oo markaa lagula dagaalamayo COVID-19, oo ay ku jiraan dhawr talaal oo lasoo xudhay oo shirkado iyo jaamacada Kanada ay wadaan, sida barnaamijyada Medicago iyo Jaamacada Saskatchewan.
In late March, the Canadian government announced C$275 million in funding for 96 research projects on medical countermeasures against COVID-19, including numerous vaccine candidates at Canadian companies and universities, such as the Medicago and University of Saskatchewan initiatives.
Ilaa wakhtigaas, dawlada Kanada ayaa ku dhawaaqday C$192 mliyan oo si gaar ah loogu sameeyay talaalka COVID-19, iyo qorshaha lagu samaynayo ee qaran "kaydka talaalka" ee dhawr talaal oo cusub oo loo isticmaali karo safmarka kale ee coronavirus marka uu yimaado.
Around the same time, the Canadian government announced C$192 million specifically for developing a COVID-19 vaccine, with plans to establish a national "vaccine bank" of several new vaccines that could be used if another coronavirus outbreak occurs.
Abriil 2 2020, cilmi baadhayaasha Jaamacada Pittsburg Waaxda Dawooyinka ayaa sheekey in la tijaabiyo PittCoVacc, talaal COVID-19 oo jiirka lagu tijaabinayo, kuwaas oo sheegey in "MNA ay bixinayso talaalka SARS-CoV-2 S1 oo markaa antigent gaarka ah ee antiboodhigu ka jawaabo ah [jiirka] kaas oo markaa bilaabmaya 2 todobaad kamid marka la isku mudo."
On 2 April 2020, researchers at the University of Pittsburgh School of Medicine reported on testing of PittCoVacc, a possible COVID-19 vaccine in mice, stating that "MNA delivered SARS-CoV-2 S1 subunit vaccines elicited potent antigen-specific antibody responses [in the mice] that were evident beginning 2 weeks after immunization."
Kanada 16 Abriil 2020, Jaacamada Waterloo Waaxda Dawooyinka ayaa ku dhawaaqday inay samaysay talaal DNA-ga ah oo markaa sanka laga qaadan karo.
In Canada on 16 April 2020, the University of Waterloo School of Pharmacy announced design of a DNA-based vaccine candidate as a possible nasal spray.
Iyada oo la isticmaalayo bacteriophages, DNA waxa loogu talo geley in lagu badalo baakteeriyada bilaa aadanka su loosoo saaro fayrus wax u eeg oo aan waxyeelo lahayn, kaas oo samayn kara nidaamka difaaca jidhka si loosoo saaro antiboodhi loogu talo geley fayruska SARS-CoV-2.
Using bacteriophages, the DNA will be designed to replicate inside human bacteria to produce harmless virus-like particles, which may stimulate the immune system to produce antibodies against the SARS-CoV-2 virus.
Maarso 2020, dawlada Maraykanka, warshadaha, iyo sadex jaamacadood ayaa isku keeney khayraadka si ay u helaan kombuyuuyar gaar ah oo IB ah, kaaas oo macluumaadkiisa laguu kaydiyo khayraadka Hewlett Packard Enterprise, Amazon, Microsoft, iyo Google.
In March 2020, the US government, industry, and three universities pooled resources to access supercomputers from IBM, combined with cloud computing resources from Hewlett Packard Enterprise, Amazon, Microsoft, and Google.
Taalaalada qaar ayaa leh isku wax qabad, sidoo kale loo yaqaan wax qabad aan la cayimin.
Some vaccines have heterologous effects, also called non-specific effects.
Taasi waxay ka dhigan tahay in laga faa'ido karo wax ka badan kahortaga xanuunka.
That means they can have benefits beyond the disease they prevent.
Tijaabada nasiibka ah ee dheeraadka ah ee Awstariya ayaa lagu doonayaa xakamaynta ku biirida 4,170 shaqaale oo daryeelka caafimaadka ah.
A further randomized trial in Australia is seeking to enrol 4,170 healthcare workers.
Waxaa macquul ah in talaalka la sameeyay in aanu amaan ahayn ama aanu waxba tarin.
It is possible vaccines in development will not be safe or effective.
Daraasadaha hordhaca ah ee talaalka lagu qiimeeyo waxtarkiisa iyada oo la isticmaalayo COVID-19 gaar ah ee xayawaanka, sida jiirka lagu muday ACE2, shaybaadhada kale ee xayawaanka, iyo wixii aan bilaa aadan ahayn, waxay muujinayaan in amaanka heerka 3 ee talaabooyinka safmarka ah ee lagaga shaqaynayo fayrus nool, iyo wada shaqaynta caalamiga ah ee lagu xaqiijinayo heerarka nidaamka amaanka ah.
Early research to assess vaccine efficacy using COVID-19-specific animal models, such as ACE2-transgenic mice, other laboratory animals, and non-human primates, indicate a need for biosafety-level 3 containment measures for handling live viruses, and international coordination to ensure standardized safety procedures.
Talaalka SARS iyo MERS ayaa lagu tijaabiyay qaababka aan bilaa aadan ahayn.